Le Lézard
Classified in: Health, Science and technology
Subjects: Photo/Multimedia, Product/Service, Webcast

CorFlow Will Report "MOCA I" Case & Initial Diagnostic Data (Late-Breaking Trial Session) at the PCR e-Course, June 25-27th, 2020


CorFlow Therapeutics AG ("CorFlow") announces today that Dr. Felice Gragnano, MD, Inselspital, Bern University Hospital, Bern, Switzerland, will present a case study and the initial diagnostic results from the MOCA I Phase 2 clinical trial during the upcoming PCR e-Course June 25-27th, 2020. The MOCA I study is a first-in-human (FIH) clinical trial to document the safety and feasibility of the CorFlow Controlled Flow Infusion (CoFItm) System in patients with acute heart attack (STEMI). Dr. Gragnano's case presentation will take place during the Clinical Cases session on Thursday, June 25th at 16:00 CET. On Saturday, June 27th at 9:00 CET, Dr. Gragnano will present the initial diagnostic data during a hot line late-breaking trial session.

The MOCA I study is a non-randomized three-phased FIH clinical trial and the Principal Investigator is Prof. Marco Valgimigli, MD, PhD, Inselspital, Bern University Hospital, Bern/Cardiocentro Ticino, Lugano, Switzerland. The MOCA I Phase 1 aimed at investigating the diagnostic feasibility in up to 18 patients with non-STEMI (NSTEMI) heart attack. Phase 2 documents the ability of the CoFItm System to measure the CorFlow proprietary dynamic Microvascular Resistance (dMVR) parameters in 20 STEMI patients. This phase investigates the correlation between periprocedural dMVR values, measured by the CoFItm System, and microvascular obstruction (MVO) quantified by magnetic resonance imaging (MRI) three days after the revascularization procedure. Finally, Phase 3 will investigate the CoFItm System's ability to be a treatment platform for safe intra-coronary delivery of therapeutic agents in 20 additional STEMI patients.

The CoFItm (COF-fee) System diagnostic dMVR technology is designed to differentiate patients with and without MVO after stent implantation in patients with acute myocardial infarction (STEMI). This will potentially help cardiologists to better manage STEMI patients in the catheter laboratory ("cathlab") without changing the established intervention workflow. In patients with substantial microvascular impairment, the CoFItm System also allows for controlled delivery of intra-coronary therapeutic agents and monitoring the treatment effect before the patients leave the cathlab.

The CoFItm System has received US Food and Drug Administration (FDA) Breakthrough Device Designation and CorFlow is planning an Early Feasibility Study (EFS) in the US using the first generation devices.

Presentations of the MOCA I case study and initial diagnostic clinical data by Dr. Felice Gragnano:
Thursday June 25th @ 16:00 CET during the PCR e-Course virtual meeting, Clinical Case Session, "MOCA I Study: microvascular obstruction measured using dMVR - Case presentation"

Saturday June 27th @ 09:00 CET during the PCR e-Course virtual meeting, Hot Line Late-Breaking Trial Session, STEMI interventions. First-in-Man and novel pharmacological strategies "Dynamic Microvascular Resistance for measuring MVO treatment (MOCA I)"

For complimentary registration and to participate in the PCR e-Course, please click https://www.pcronline.com/Courses/PCR-e-Course/Attend

About CorFlow Therapeutics AG

CorFlow Therapeutics (www.corflow-therapeutics.ch) is incorporated in Baar, Switzerland, and is developing proprietary technologies to measure the coronary microvascular status and provide therapy to the compromised coronary microcirculation at the same time in the catheter laboratory. Microvascular obstruction (MVO) after an acute heart attack is documented to be an independent marker leading to costly complications such as heart failure. The CorFlow technologies may enable interventional cardiologists to treat MVO in severe heart attack patients, thereby potentially reducing the short- and long-term complication rates in these patients.

Caution: The CorFlow Controlled Flow Infusion (CoFITM) technology is in the early phases of development. The CoFITM System is approved for use in the MOCA I clinical trial in Switzerland. It will not be available in other European countries, the US or Japan for other clinical trials until further notice and is NOT available for sale. This news release contains certain "forward-looking" statements under the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements, which may include, but are not limited to, statements concerning the projections, financial condition, results of operations and businesses of CorFlow are based on management's current expectations and estimates and involve risks and uncertainties that could cause actual results or outcomes to differ materially from those contemplated by the forward-looking statements. Factors that could cause or contribute to such differences may include, but are not limited to, risks relating to the protection of intellectual property, changes to governmental regulation of medical devices, European or US Food and Drug Administration (FDA) approvals of new products, the impact of competitive products, changes to the competitive environment, the acceptance of new products in the market, conditions of the interventional cardiology industry and the economy and other factors.


These press releases may also interest you

at 11:30
The "Global Antibody Therapeutic Market: Focus on Format, Disease Area, Route of Administration, End Users, Region, and Competitive Landscape - Analysis and Forecast, 2024-2033" report has been added to  ResearchAndMarkets.com's offering. The global...

at 11:30
XtalPi Inc., a leading global technology company in integrating artificial intelligence (AI) and robotics to advance the discovery of groundbreaking medicine and innovative materials, announced today the launch of its proprietary comprehensive solid...

at 11:25
Manifest Technologies, Inc., developer of an AI-powered computational neuro-imaging platform for CNS disease, today unveiled the company after completing its initial funding and partnership with a top five global pharmaceutical company. Today, over...

at 11:08
Sunwave Health, a leader in healthcare technology, proudly announces the launch of MARA, a patent-pending, innovative AI Agent designed to transform the landscape of behavioral health documentation. Since its launch on October 25, 2023, MARA has...

at 11:04
MelliCell Inc. has been awarded a U.S. National Science Foundation (NSF) Small Business Innovation Research (SBIR) grant for $275,000 to conduct research and development (R&D) work on "Industrial Scale Technology for Drug Development in Mature Human...

at 11:00
Eagle Hill Consulting has earned another top workplace award, this time selected by The Washington Business Journal as a 2024 Best Places to Work in the extra-large sized company category. Eagle Hill also has earned multiple best workplace awards...



News published on and distributed by: